Drugs such as infliximab (TNF family), etanercept (TNF family), tocilizumab (IL-6), and anakinra (IL-1), have also been evaluated as cytokine-targeted therapies in Sjögren’s Syndrome. This evidence concerns the gene IL6 and Sjogren syndrome.